<DOC>
	<DOC>NCT02576145</DOC>
	<brief_summary>This study will assess whether daclizumab impairs the ability of children receiving a kidney transplant to elicit a primary immune response. The anticipated time on study treatment is 1 day, and the target sample size is 82 individuals.</brief_summary>
	<brief_title>A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)</brief_title>
	<detailed_description />
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Primary renal transplant recipients between 2 and 19 years of age Receiving or have received daclizumab in the previous 418 months Receiving or have received daclizumab less than (&lt;) 24 hours pretransplant and additional courses every other week Single organ recipients (kidney only) Previous vaccination with tetanus toxoid (TT) prior to transplant Receiving a maintenance immunosuppression regimen of a calcineurin inhibitor, mycophenolate mofetil, and prednisone (or equivalent corticosteroid) Received intravenous gamma globulin or a TT vaccination since transplant Experienced rejection within 3 months of receiving study vaccinations and/or treated with lymphocyte preparation or methylprednisolone to reverse suspected acute rejection within 3 months of receiving study vaccinations Received any vaccine within 30 days of receiving study vaccinations Received plasmapheresis treatment or growth hormone treatment since transplant</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>